KRP-108 long term study
Phase 3
- Conditions
- Asthma
- Registration Number
- JPRN-jRCT2080221304
- Lead Sponsor
- Kyorin Pharmaceutical Co.,LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients treated with ICS(100-1000ug/day fluticasone propionate conversion) during 4 weeks before Visit1
-Patients whose FEV1.0 over 40% of predicted value.
-Out patients
And others.
Exclusion Criteria
-Patients who have previous/concurrent disease of malignant tumor
-Patients who were hospitalization caused by exacerbation during 1 year before Vist1
-Patients who have lung infection currently
-Patients treated with systemic steroids during 4 weeks before Visit1(except as-needed use less than defined dose)
-Patients who have irreversible lung disease such as pulmonary fibrosis
And others.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method